Media Articles Related to Aloxi (Palonosetron)
Netupitant/palonosetron for prevention of nausea and vomiting: Added benefit not proven
Source: Cancer / Oncology News From Medical News Today [2015.11.24]
Certain advantages in side effects, but equivalence of main effect has not been proven.
Nausea and Vomiting
Source: MedicineNet Angina Specialty [2014.07.09]
Title: Nausea and Vomiting
Category: Diseases and Conditions
Created: 1/31/2005 8:21:00 AM
Last Editorial Review: 7/9/2014 12:00:00 AM
Published Studies Related to Aloxi (Palonosetron)
Comparison of an extended-release formulation of granisetron (APF530) versus
palonosetron for the prevention of chemotherapy-induced nausea and vomiting
associated with moderately or highly emetogenic chemotherapy: results of a
prospective, randomized, double-blind, noninferiority phase 3 trial. 
highly emetogenic chemotherapy (HEC)... CONCLUSIONS: A single subcutaneous APF530 injection offers a convenient
Effect of palonosetron on the QTc interval in patients undergoing sevoflurane
sevoflurane anaesthesia and receive palonosetron... CONCLUSIONS: There was no significant difference in the QTc intervals during the
Efficacy of oral palonosetron compared to intravenous palonosetron for the
prevention of chemotherapy-induced nausea and vomiting associated with moderately
emetogenic chemotherapy: a phase 3 trial. 
palonosetron formulation has been developed and compared to the IV formulation... CONCLUSION: Oral palonosetron has a similar efficacy and safety profile as IV
Anti-emetic effect of ondansetron and palonosetron in thyroidectomy: a
prospective, randomized, double-blind study. 
high-risk patients receiving i.v. PCA after thyroidectomy... CONCLUSIONS: Palonosetron is more effective than ondansetron for high-risk
Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. [2011.04]
BACKGROUND: Explore safety and efficacy of three palonosetron-containing regimens for emesis prevention over 7 days in multiple myeloma (MM) patients receiving melphalan (100 mg/m(2)) and hematopoietic stem cell transplantation (HSCT)... CONCLUSIONS: Palonosetron with dexamethasone was safe and effective in preventing emesis in MM patients receiving melphalan and HSCT. This pilot study with a limited number of patients suggests that multiple doses of palonosetron could be more effective than a single dose in making patients emesis free without need for rescue medication. However, even multiple doses of palonosetron resulted in only 20% of patients being emesis free without rescue medication, suggesting that further improvement will require development of more effective combination antiemetic therapy. (c) The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
Clinical Trials Related to Aloxi (Palonosetron)
Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI) [Completed]
The goal of this clinical research study is to compare 2 treatment schedules of Aloxi
(palonosetron) in patients with sarcoma who are receiving chemotherapy with adriamycin and
ifosfamide. The safety of the drug and schedules will be studied. The effect of
palonosetron on patients' quality of life (QOL) will also be studied.
Palonosetron Plus Aprepitant Versus Palonosetron in Preventing Nausea and Vomiting in Leukemic Patients [Recruiting]
The aim of present study is to evaluate if the addition of Aprepitant to multiple doses of
palonosetron IV enhances the efficacy of multiple doses of palonosetron IV alone, in
preventing CINV in AML or High risk MDS patient, treated with multiple days chemotherapy.
Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab [Terminated]
Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide [Completed]
1. Purpose and objective:
1. To determine the safety and tolerability of palonosetron in the prevention of radiation
induced nausea and vomiting (RINV) in primary glioma patients receiving radiation (RT)
and concomitant temozolomide (TMZ).
2. To determine the efficacy of palonosetron in primary glioma patients receiving six
weeks of RT and concomitant TMZ
3. To evaluate the effect s of palonosetron on the quality of life of primary glioma
patients receiving six weeks of RT and Concomitant TMZ.
2. Study activities and Population group: We will conduct a phase II single arm trial of
Palonosetron (PALO) for the prevention of RINV in primary malignant glioma patients
receiving radiation therapy (RT) and concomitant temozolomide (TMZ). All eligible patients
should receive a planned total dose of 54-60 GY of radiation and 75 mg/m2 of daily
temozolomide for a total of six weeks of treatment. For each week of radiation patients will
receive a single 0. 25 mg intravenous dose of palonosetron 30 minutes before each week of
radiation fraction. This schedule will be repeated for each week of radiation for a total of
6 weeks. Forty subjects with gliomas will participate.
3. Data analysis and risk/safety issues: The frequency of toxicity will be summarized by
type and the most severe grade experienced. The complete response rate, defined as the
proportion of patients with no emetic episode or use of rescue medication while receiving
radiation and concomitant temozolomide, will be estimated with a 95% confidence interval.
Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting [Completed]
The goal of this clinical research study is to compare the effectiveness of 3 drug schedules
in preventing chemotherapy-related nausea and/or vomiting in patients with acute myelogenous
leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
Reports of Suspected Aloxi (Palonosetron) Side Effects
Abdominal Pain (2),
Weight Decreased (2),
DRY Mouth (2),
Anaphylactoid Reaction (2),
Blood Creatinine Increased (2),
Muscle Spasms (2), more >>